Related Experiment Videos
Novel N1-(benzyl)cinnamamidine derived NR2B subtype-selective NMDA receptor antagonists
Neil R Curtis1, Helen J Diggle, Janusz J Kulagowski
1Department of Medicinal Chemistry, Merck Sharp & Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK. neil_curtis@merck.com
Bioorganic & Medicinal Chemistry Letters
|March 18, 2003
Abstract:
Novel (E)-N(1)-(benzyl)cinnamamidines were prepared and evaluated as NR2B subtype NMDA receptor ligands. Excellent affinity was achieved by appropriate substitution of either phenyl ring. The 2-methoxybenzyl compound 1h had approximately 1,000-fold lower IC(50) in NR2B than NR2A-containing cells. Replacement of the styryl unit by 2-naphthyl was well tolerated.